Stephen Haggarty is the Director of Chemical Neurobiology at the Broad Institute. He is also a Faculty member at Harvard Medical School and Massachusetts General Hospital. His research focuses on gaining a fundamental understanding of the molecular mechanisms of neuroplasticity that underlie the ability of the nervous system to sense, adapt, and respond to a variety of internal and external stimuli and translating this knowledge into the discovery of novel targeted therapeutics for the treatment of neuropsychiatric disorders.

His laboratory, the Chemical Neurobiology Laboratory, has developed multiple neuronal cell-based assays to investigate the response of neuronal cells to thousands of different chemical probes, leading to the discovery, characterization, and optimization of novel chemical probes of critical neuroplasticity processes. The laboratory is also working on the application of methods for generating patient-specific stem cell models of neuropsychiatric disorders and advancing a platform for human experimental neurobiology and novel therapeutic discovery based around the use of stem-cell human neurons for functional genomic studies in combination with high-throughput screening.

Dr. Haggarty received a B.S. in genetics from the University of British Columbia, Vancouver, and a Ph.D. in biochemistry from Harvard University in the laboratory of Stuart Schreiber.